Enzybiotics LYSSTAPH-S and LYSDERM-S as Potential Therapeutic Agents for Chronic MRSA Wound Infections

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

VACEK Lukáš KOBZOVÁ Šárka ČMELÍK Richard PANTŮČEK Roman JANDA Lubomír

Year of publication 2020
Type Article in Periodical
Magazine / Source Antibiotics
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.mdpi.com/2079-6382/9/8/519
Doi http://dx.doi.org/10.3390/antibiotics9080519
Keywords enzyme therapy; enzybiotics; lysostaphin; LYSSTAPH-S; endolysin; LYSDERM-S; MRSA
Attached files
Description Antibacterial antibiotic therapy has played an important role in the treatment of bacterial infections for almost a century. The increasing resistance of pathogenic bacteria to antibiotics leads to an attempt to use previously neglected antibacterial therapies. Here we provide information on the two recombinantly modified antistaphylococcal enzymes derived from lysostaphin (LYSSTAPH-S) and endolysin (LYSDERM-S) derived from kayvirus 812F1 whose target sites reside in the bacterial cell wall. LYSSTAPH-S showed a stable antimicrobial effect over 24-h testing, even in concentrations lower than 1 mu g/mL across a wide variety of epidemiologically important sequence types (STs) of methicillin-resistantStaphylococcus aureus(MRSA), especially in the stationary phase of growth (status comparable to chronic infections). LYSDERM-S showed a less potent antimicrobial effect that lasted only a few hours at concentrations of 15 mu g/mL and higher. Our data indicate that these antimicrobial enzymes could be of substantial help in the treatment of chronic MRSA wound infections.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.